Breast Cancer Treatment: A Modern, Evidence-Based Guide to Multimodal Therapy

Breast cancer remains the most frequently diagnosed malignancy worldwide, representing a complex spectrum of disease rather than a singular clinical entity. Over the past two decades, the therapeutic landscape has underwent a profound paradigm shift. Modern oncology has transitioned away from a one-size-fits-all approach toward highly individualized, multimodal treatment regimens guided by precise molecular profiling.

When a patient receives a diagnosis, clinical teams construct a therapeutic strategy based on disease staging, genetic risk, and receptor status. Understanding the interplay between surgery, systemic therapies, and radiation is essential to optimizing survival and preserving patient quality of life.

Molecular Subtyping: The Foundation of Treatment Design

Before initiating therapy, pathological evaluation of the tumour tissue via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is mandatory. This testing classifies breast cancer into three primary molecular subtypes, which dictate the entire treatment trajectory:

1. Hormone Receptor-Positive (HR+ ): Tumours expressing Oestrogen Receptors (ER) and/or Progesterone Receptors (PR). These represent roughly 70% of cases and are primarily driven by hormonal signalling.
2. Human Epidermal Growth Factor Receptor 2-Positive (HER2+): Tumours characterized by an overexpression of the HER2 protein or amplification of the $ERBB2$ gene, leading to aggressive tumour cell proliferation.
3. Triple-Negative Breast Cancer (TNBC): Tumours lacking ER, PR, and HER2 expression. TNBC accounts for 10-15% of cases, carries a higher risk of early recurrence, and relies heavily on cytotoxic and immunotherapeutic interventions.

The Modalities of Treatment

The standard of care for breast cancer utilizes a combination of local and systemic therapies, sequenced strategically to maximize efficacy.

1. Surgical Interventions and Local Control

Surgery aims to achieve clear margins (rejection of the tumour with no cancer cells at the outer edge). The two primary surgical pathways are:

• Breast-Conserving Surgery (BCS / Lumpectomy): Removal of the tumour along with a small rim of healthy tissue, preserving the native breast architecture. BCS is almost always paired with adjuvant radiation therapy.
• Mastectomy: Total removal of the breast tissue. This may be elected due to tumour size, multicentric disease, genetic predisposition (e.g., BRCA1/2) mutations), or patient preference.

Axillary staging via a Sentinel Lymph Node Biopsy (SLNB) is performed concurrently to evaluate potential lymphatic dissemination while minimizing the risk of lymphedema associated with a full axillary lymph node dissection.

2. Systemic Therapies: Neoadjuvant vs. Adjuvant

Systemic treatment circulates throughout the body to eradicate micrometastatic disease. It can be delivered neoadjuvantly (before surgery to shrink the tumour) or adjuvantly (after surgery to prevent recurrence).

• Cytotoxic Chemotherapy: Anthracycline and taxane-based regimens remain backbone therapies, particularly for TNBC and high-risk HR+ or HER2+ tumors.
• Endocrine Therapy: For HR+ malignancies, suppressing oestrogen signaling is paramount. Pre-menopausal women typically receive Tamoxifen (a Selective Oestrogen Receptor Modulator, or SERM), while post-menopausal women are prescribed Aromatase Inhibitors (AIs) like Anastrozole or Letrozole, which block the peripheral conversion of androgens to oestrogen. In high-risk cases, ovarian function suppression (OFS) is combined with an AI.
• Targeted Biological Therapies: The introduction of monoclonal antibodies like Trastuzumab and Pertuzumab revolutionized HER2+ breast cancer treatment by selectively binding to the extracellular domain of the HER2 receptor, blocking downstream proliferative cascades. Additionally, Antibody-Drug Conjugates (ADCs) like Trastuzumab Deruxtecan (T-Dxd) act as "Trojan horses," delivering potent cytotoxic payloads directly into HER2-expressing cells.
• Immunotherapy: Immune checkpoint inhibitors, such as Pembrolizumab (anti-PD-1), have become standard of care in high-risk early-stage and metastatic TNBC, unleashing the patient’s T-cells to identify and destroy malignant mutations.

3. Radiation Therapy

Radiation uses high-energy X-rays to eliminate residual microscopic disease following surgery. It is strictly indicated for patients undergoing BCS and for those with advanced nodal disease or positive margins following a mastectomy. Modern delivery techniques, such as deep inspiration breath-hold (DIBH), shield vital underlying organs like the heart from radiation exposure.

Clinical Staging and Survival Outcomes

Therapeutic sequencing varies drastically based on the clinical stage at presentation. Data compiled by the National Cancer Institute’s SEER database underlines the critical value of early therapeutic intervention.

Conclusion

The treatment of breast cancer has advanced into an era of precision medicine. By integrating genomic assays (such as Oncotype DX or MammaPrint) for HR+ disease, clinicians can safely spare low-risk patients from the toxicity of chemotherapy. Simultaneously, targeted therapies and immunotherapies continue to extend the survival of patients facing more aggressive phenotypes. Continued survival gains rest upon early detection, molecular precision, and the coordinated execution of a multidisciplinary care team.